Clinical Trial Update: Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of EPI-506 for metastatic castration-resistant prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• EPI-506

Snippet

Sponsor: ESSA Pharmaceuticals | Conditions: Prostatic Neoplasms, Genital Neoplasms, Male | Phase 1, Phase 2 | Status: TERMINATED